Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
99 SEK | +5.77% | +0.20% | +25.95% |
May. 08 | Transcript : Devyser Diagnostics AB, Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Devyser Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 118
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Hereditary Diseases
65.0
%
| - | - | 110 | 65.0 % | - |
Oncology
20.0
%
| - | - | 34 | 20.0 % | - |
Transplantation
15.0
%
| - | - | 25 | 15.0 % | - |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe (excluding Sweden), Middle East and Africa
82.3
%
| 109 | 85.7 % | 139 | 82.3 % | +28.42% |
North and South America
8.2
%
| 3 | 2.5 % | 14 | 8.2 % | +333.96% |
Sweden
5.9
%
| 11 | 8.4 % | 10 | 5.9 % | -6.06% |
Asia
3.6
%
| 4 | 3.4 % | 6 | 3.6 % | +43.77% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ulf Axel Klangby
FOU | Founder | 55 | 03-12-31 |
Fredrik Alpsten
CEO | Chief Executive Officer | 58 | - |
Sabina Berlin
DFI | Director of Finance/CFO | 41 | 20-12-31 |
Göran Rydin
COO | Chief Operating Officer | 55 | 20-12-31 |
Camilla Wiberg
HRO | Human Resources Officer | - | 22-08-31 |
Theis Kipling
PRN | Corporate Officer/Principal | - | 22-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 70 | 20-12-31 | |
Director/Board Member | 52 | 21-12-31 | |
Chairman | 55 | 09-12-31 | |
Lars Höckenström
BRD | Director/Board Member | 68 | 15-12-31 |
Ulf Axel Klangby
FOU | Founder | 55 | 03-12-31 |
Fredrik Dahl
BRD | Director/Board Member | - | 20-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 16,284,469 | 8,370,589 ( 51.40 %) | 0 | 51.40 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.95% | 141M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- DVYSR Stock
- Company Devyser Diagnostics AB